BIOPHYTIS (ALBPS.PA) Stock Price & Overview

EPA:ALBPS • FR001400OLP5

Current stock price

0.0296 EUR
0 (-8.36%)
Last:

The current stock price of ALBPS.PA is 0.0296 EUR. Today ALBPS.PA is down by -8.36%. In the past month the price decreased by -48.97%. In the past year, price decreased by -90.89%.

ALBPS.PA Key Statistics

52-Week Range0.0293 - 0.404
Current ALBPS.PA stock price positioned within its 52-week range.
1-Month Range0.0293 - 0.0585
Current ALBPS.PA stock price positioned within its 1-month range.
Market Cap
339.222K
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.84
Dividend Yield
N/A

ALBPS.PA Stock Performance

Today
-8.36%
1 Week
-34.95%
1 Month
-48.97%
3 Months
-57.04%
Longer-term
6 Months -82.17%
1 Year -90.89%
2 Years -97.89%
3 Years -99.83%
5 Years -99.99%
10 Years N/A

ALBPS.PA Stock Chart

BIOPHYTIS / ALBPS Daily stock chart

ALBPS.PA Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to ALBPS.PA. When comparing the yearly performance of all stocks, ALBPS.PA is a bad performer in the overall market: 99.49% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
ALBPS.PA Full Technical Analysis Report

ALBPS.PA Earnings

Next Earnings DateJul 9, 2026
Last Earnings DateN/A
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
ALBPS.PA Earnings History

ALBPS.PA Forecast & Estimates

9 analysts have analysed ALBPS.PA and the average price target is 0.79 EUR. This implies a price increase of 2553.38% is expected in the next year compared to the current price of 0.0296.

For the next year, analysts expect an EPS growth of 51.91% and a revenue growth -78.57% for ALBPS.PA


Analysts
Analysts84.44
Price Target0.79 (2568.92%)
EPS Next Y51.91%
Revenue Next Year-78.57%
ALBPS.PA Forecast & Estimates

ALBPS.PA Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

ALBPS.PA Financial Highlights

Over the last trailing twelve months ALBPS.PA reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 87.11% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-8.03M
Industry RankSector Rank
PM (TTM) N/A
ROA -121.24%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%89.18%
Sales Q2Q%N/A
EPS 1Y (TTM)87.11%
Revenue 1Y (TTM)N/A
ALBPS.PA financials

ALBPS.PA Ownership

Ownership
Inst Owners4.53%
Shares11.46M
Float11.35M
Ins Owners0.39%
Short Float %N/A
Short RatioN/A
ALBPS.PA Ownership

ALBPS.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ARGX ARGENX SE25.3538.17B
1AE ARGENX SE25.3738.17B
22UA BIONTECH SE-ADR N/A19.092B
ABVX ABIVAX SA N/A8.477B
2X1 ABIVAX SA N/A8.445B
GLPG GALAPAGOS NV N/A1.877B
GXE GALAPAGOS NV N/A1.877B
NANO NANOBIOTIX N/A1.42B
6IV INVENTIVA SA N/A1.087B
IVA INVENTIVA SA N/A1.071B
PHIL PHILOGEN SPA18.09657.9M
XUP GENFIT917.65468.027M
GNFT GENFIT869.12429.025M

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges

About ALBPS.PA

Company Profile

ALBPS logo image Biophytis SA operates as a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France and currently employs 18 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.

Company Info

IPO: 2015-07-13

BIOPHYTIS

14 avenue de l'Opera

Paris ILE-DE-FRANCE FR

Employees: 22

ALBPS Company Website

ALBPS Investor Relations

Phone: 33141836600

BIOPHYTIS / ALBPS.PA FAQ

What does ALBPS do?

Biophytis SA operates as a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France and currently employs 18 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.


What is the current price of ALBPS stock?

The current stock price of ALBPS.PA is 0.0296 EUR. The price decreased by -8.36% in the last trading session.


What is the dividend status of BIOPHYTIS?

ALBPS.PA does not pay a dividend.


How is the ChartMill rating for BIOPHYTIS?

ALBPS.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


What is the expected growth for ALBPS stock?

The Revenue of BIOPHYTIS (ALBPS.PA) is expected to decline by -78.57% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Can you provide the number of employees for BIOPHYTIS?

BIOPHYTIS (ALBPS.PA) currently has 22 employees.


When does BIOPHYTIS (ALBPS.PA) report earnings?

BIOPHYTIS (ALBPS.PA) will report earnings on 2026-07-09.